Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?

Am J Ophthalmol. 2011 Sep;152(3):329-331. doi: 10.1016/j.ajo.2011.05.040.

Authors

Laurence S Lim¹, Chui Ming Gemmy Cheung¹, Paul Mitchell², Tien Y Wong³

Affiliations

¹ Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
² Centre for Vision Research, University of Sydney, Sydney, Australia.
³ Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Department of Ophthalmology, National University of Singapore, Singapore. Electronic address: [email protected].

PMID: 21855670
DOI: 10.1016/j.ajo.2011.05.040

No abstract available

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / adverse effects*
Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Diabetic Retinopathy / drug therapy
Humans
Infant, Newborn
Macular Degeneration / drug therapy
Ophthalmology / standards
Practice Guidelines as Topic
Ranibizumab
Retinal Vein Occlusion / drug therapy
Retinopathy of Prematurity / drug therapy
Therapeutic Equivalency
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Visual Acuity

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
VEGFA protein, human
Vascular Endothelial Growth Factor A
Bevacizumab
Ranibizumab